XOMA Royalty Q3 2025 Earnings Results & Report

XOMA Royalty EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.02
• Beat/Miss: Missed by -$0.33
• One Year Ago EPS: N/A
• EPS Beat Rate: 4 of last 8 quarters

XOMA Royalty Revenue Results

• Actual Revenue: $9.35 million
• Expected Revenue: $11.47 million
• Beat/Miss: Missed by -$2.12 million
• YoY Revenue Growth: N/A

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.